Pharmaceutical Technology2 天
Carperitide by Daiichi Sankyo for Contrast Induced Nephropathy: Likelihood of Approval
Carperitide is under clinical development by Daiichi Sankyo and currently in Phase II for Contrast Induced Nephropathy.